1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Intervacc AB (publ)

Intervacc AB (publ)

IVACC.ST
Intervacc AB (publ)SE flagStockholm Stock Exchange
1.32
SEK
+0.02
- -
449.19MMarket Cap
Intervacc AB (publ)
IVACC.ST
(Stockholm Stock Exchange)

Recent

price

1.32

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
3.48
2.8
3.58
2.22
0.87
0.23
0.08
0.08
0.14
0.09
0.13
0.07
0.06
Revenue per Share
0.42
0.01
-0.44
-0.59
-0.67
-0.53
-0.41
-0.44
-0.95
-1.17
-0.86
-0.27
-0.26
Basic EPS, GAAP
- -
-0.85
-1.07
-1.49
-0.69
-0.8
-0.34
-0.4
-1.06
-0.53
-0.61
-0.23
-0.21
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
1.44
1.49
1.84
1.64
1.59
1.49
1.49
1.72
0.17
0.23
0.2
Book Value per Share
-0.39
0.51
0.66
1.77
1.33
0.96
2.58
1.74
1.1
0.95
0.3
0.52
0.4
Tangible Book Value per Share
22
22
16
22
41
53
63
67
68
88
88
297
341
Basic Weighted Avg Shares
78
63
56
48
36
12
5
5
10
8
12
20
19
Sales/Revenue/Turnover
12.95
3.31
-13.31
-28.5
-86.85
-229.41
-537.15
-560.83
-665.15
-1,167.55
-655.61
-415.7
-488.12
Operating Margin (%)
6
6
6
6
15
6
6
6
21
25
19
19
19
Depreciation Expense
9
- -
-7
-13
-27
-28
-26
-29
-64
-103
-76
-81
-89
Net Income, GAAP
2.86
89.36
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
11.94
0.22
-12.25
-26.6
-77.22
-229.77
-535.59
-560.48
-662.52
-1,283.24
-640.66
-402.32
-473.17
Profit Margin (%)
2
19
13
32
43
39
151
105
62
83
26
156
135
Working Capital
- -
- -
8
1
1
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
102
127
130
165
190
220
338
308
250
238
162
275
253
Total Equity
- -
0.19
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
-61.09
-46.79
-51.09
-34.45
-27.39
-29.28
-63.74
-81.48
-90.64
-194.01
-131.11
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
341
341
341
Market Capitalization
244
275
281

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
206
175
160
Cash, Cash Equivalents & STI
172
161
146
Accounts Receivable, Net
- -
1
- -
Inventories
27
10
10
Total Current Liabilities
19
19
25
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.92%
1.03%
69.35%
Free Cash Flow
26.85%
39.99%
24.75%
Net Income, GAAP
-465.95%
34.78%
7.02%
Sales/Revenue/Turnover
1.71%
38.93%
70.42%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2
3
3
4
12
2025
5
7
5
3
20
2026
3
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.2
-0.2
-0.25
-0.2
-0.86
2025
-0.08
-0.05
-0.04
-0.1
-0.27
2026
-0.06
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (BML.WA)
Odyssey Therapeutics, Inc. (ODTX)
Qrons Inc. (QRON)
Whitehawk Therapeutics Inc (WHWK)
PhaseBio Pharmaceuticals, Inc. (PHAS)
Annexin Pharmaceuticals AB (ANNX.ST)
Business
Intervacc AB (publ) is a Swedish biotechnology company dedicated to advancing animal health through the discovery and development of innovative vaccines against bacterial infections. The company leverages a proprietary technology platform centered on recombinant proteins to create safe and effective preventative solutions. Its primary commercial offering, Strangvac, is a vaccine for equine strangles, a highly contagious streptococcal infection affecting horses. Strangvac is approved across the European Union, the United Kingdom, and other European markets, with active distribution in numerous countries and aspirations for broader international reach, including the United States. Intervacc recently extended its significant distribution agreement with Dechra Pharmaceuticals for Strangvac by two years. Beyond its flagship product, Intervacc maintains an active research pipeline, including INV274, a vaccine candidate targeting Streptococcus suis infections in piglets, a project that has received Eurostars 3 grant funding. The company also previously pursued a vaccine candidate, INV412, against Staphylococcus aureus infections causing mastitis in dairy cows, though this project has been paused. Supplementing its vaccine development, Intervacc operates through subsidiaries such as Nordvacc Läkemedel AB, which markets and distributes veterinary pharmaceuticals and vaccines across Nordic and certain European markets, and Mybac-Vettech AB, an ISO-certified laboratory providing specialized diagnostic services in veterinary bacteriology and mycology within Sweden. The company has successfully secured substantial financing through a recent rights issue to fuel its growth initiatives, including the acceleration of Strangvac sales and the progression of its pipeline. Intervacc is headquartered in Hägersten, Sweden.